Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)
Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –
Kiniksa Pharmaceuticals International total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
No total debt figures for Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?